This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
awmsg logo

nevirapine (Viramune®)

Reference No. 1581

Publication date:

Last review date:

Appraisal information

nevirapine (Viramune®) 50 mg prolonged-release tablet
nevirapine (Viramune®) 100 mg prolonged-release tablet
nevirapine (Viramune®) 400 mg prolonged-release tablet

Company: Boehringer Ingelheim Ltd
BNF category: Infections
NMG meeting date: 15/05/2012
AWMSG meeting date: 20/06/2012
Submission Type: Limited Submission
Status: Recommended
Advice No: 1612
Ratification by Welsh Government: 23/07/2012

Current Progress

Ratification by
Welsh Government

AWMSG advice

Nevirapine (Viramune®) prolonged release tablets are recommended as an option for use within NHS Wales in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus type 1 (HIV-1) infected adults, adolescents, and children three years and above and able to swallow tablets. Prolonged release tablets are not suitable for the 14-day lead-in phase for patients starting nevirapine. Other nevirapine formulations, such as immediate release tablets or oral suspension should be used. Most of the experience with Viramune® is in combination with nucleoside reverse transcriptase inhibitors (NRTIs). The choice of a subsequent therapy after Viramune® should be based on clinical experience and resistance testing.
Final Appraisal Recommendation (FAR)
AWMSG Secretariat Appraisal Report (ASAR)
Clinical Expert (CE) Summary